サンプル依頼リスト カート
  • English
  • Korean
表紙：尿路上皮がん治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415694

尿路上皮がん治療の世界市場レポート 2024年

Urothelial Carcinoma Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
尿路上皮がん治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

尿路上皮がん治療の市場規模は近年急速に拡大しています。2023年の24億1,000万米ドルから2024年には28億6,000万米ドルに、CAGR18.8％で拡大します。実績期間の成長は、尿路上皮がんの有病率の上昇、尿路上皮がんに対する意識の高まり、ヘルスケアへのアクセスの増加、可処分所得の上昇に起因しています。

尿路上皮がん治療市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR16.9％で53億3,000万米ドルに成長します。予測期間の成長は、人口の高齢化、個別化医療への需要、尿路上皮がんの研究と治療に対する政府支援の増加、尿路上皮がん治療への投資の増加に起因しています。予測期間における主な動向は、バイオマーカー主導型治療、ネオアジュバントおよびアジュバントアプローチ、リキッドバイオプシー、低侵襲手術、化学療法開発、デジタルヘルス技術などです。

膀胱がん患者の急増は、当面の尿路上皮がん治療市場拡大の大きな促進要因になると予測されます。膀胱がんは、主に膀胱を覆う細胞を侵すがんの一種で、患者やヘルスケアプロバイダーが求めるさまざまな治療オプションが必要となります。膀胱がんに関する詳細な研究は、標的療法の開発に情報を提供し、尿路上皮がんに関する貴重な洞察を提供し、治療成績の向上を約束する学際的アプローチを促進します。例えば、2022年1月、米国がん協会（American Cancer Society Inc.）のデータから、米国における泌尿器膀胱がんの推定症例数は2021年に83,730例に達し、2020年に報告された81,400例から2.8％増加したことが明らかになった。このような膀胱がん症例の増加動向は、尿路上皮がん治療市場を牽引するものとみられます。

化学療法に対する需要の高まりは、当面の尿路上皮がん治療市場成長の重要な促進要因になると予測されます。化学療法は、体内で急速に分裂する細胞を標的とし、それを根絶するために薬剤を使用する医療行為であり、一般的にがん治療に採用されています。化学療法の極めて重要な役割は、様々な病期の管理に有効であることに起因しており、尿路上皮がん治療において不可欠なアプローチとなっています。例えば、米国を拠点とする医療情報プロバイダーであるMesothelioma.comによると、2023年6月現在、米国のがん患者の約25％が毎年化学療法を受けています。したがって、化学療法に対する需要の増加は、尿路上皮がん治療市場を促進することになります。

2023年の尿路上皮がん治療市場では北米が最大地域でした。尿路上皮がん治療レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の尿路上皮がん治療市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 非浸潤性尿路上皮がんの治療
  • 浸潤性尿路上皮がんの治療
  • 世界の尿路上皮がん治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 免疫療法
  • 放射線療法
  • 化学療法
  • 世界の尿路上皮がん治療市場、がんタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 膀胱がん
  • 尿道がん
  • 尿管がんと腎盂がん
  • 世界の尿路上皮がん治療市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 在宅ケア
  • 専門センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の尿路上皮がん治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の尿路上皮がん治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 尿路上皮がん治療市場の競合情勢
  • 尿路上皮がん治療市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • AbbVie Inc.

第31章 その他の主要および革新的な企業

  • Bayer AG
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Abbott Laboratories Inc.
  • GlaxoSmithKline PLC
  • Astellas Pharma Inc.
  • Agilent Technologies Inc.
  • Eisai Co. Ltd
  • Incyte Corporation
  • Hikma Pharmaceuticals PLC
  • Amneal Pharmaceuticals LLC
  • Seagen Inc.
  • Lupin Limited
  • Genentech Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12293

“Urothelial Carcinoma Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urothelial carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urothelial carcinoma treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The urothelial carcinoma treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Non-Invasive Urothelial Carcinoma Treatment; Invasive Urothelial Carcinoma Treatment
  • 2) By Treatment: Immunotherapy; Radiotherapy; Chemotherapy
  • 3) By Cancer Type: Bladder Cancer; Urethral Cancer; Ureteric And Renal Pelvic Cancer
  • 4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Urothelial carcinoma is a form of cancer that originates in the urothelial cells lining the interior of the urinary system, encompassing the bladder, ureters (connecting tubes between the kidneys and the bladder), and the renal pelvis (the kidney segment responsible for collecting urine). Treatments for urothelial carcinoma, involving both surgical procedures and intravenous therapies, play a crucial role in managing the disease, enhancing patient outcomes, and improving their quality of life.

The primary categories of urothelial carcinoma treatment are non-invasive and invasive. Non-invasive treatment pertains to addressing early-stage bladder cancer that has not spread to the deeper layers of the bladder or surrounding tissues. This is achieved through techniques like transurethral resection of bladder tumors (TURBT), which entails the removal of cancerous tissue from the bladder lining, and intravesical therapies, where medications are directly delivered into the bladder to prevent recurrence. These treatments, encompassing immunotherapy, radiotherapy, and chemotherapy, are also employed to address various types of urinary system cancers, including bladder, urethral, ureteric, and renal pelvic cancers. These treatments serve a variety of end users, including hospitals, homecare services, specialty centers, and others.

The urothelial carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides urothelial carcinoma treatment market statistics, including urothelial carcinoma treatment industry global market size, regional shares, competitors with a urothelial carcinoma treatment market share, detailed urothelial carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the urothelial carcinoma treatment industry. This urothelial carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urothelial carcinoma treatment market size has grown rapidly in recent years. It will grow from $2.41 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to rising prevalence of urothelial carcinoma, growing awareness of urothelial carcinoma, increasing access to healthcare, rising disposable incomes.

The urothelial carcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $5.33 billion in 2028 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to aging population, demand for personalized medicine, rising government support for urothelial carcinoma research and treatment, growing investments on urothelial carcinoma treatment. Major trends in the forecast period include biomarker-driven therapies, neoadjuvant and adjuvant approaches, liquid biopsies, minimally invasive surgeries, chemotherapy development, digital health technologies.

The surge in bladder cancer cases is anticipated to be a significant driver for the expansion of the urothelial carcinoma treatment market in the foreseeable future. Bladder cancer is a prevalent form of cancer that primarily affects the cells lining the urinary bladder, necessitating a variety of treatment options sought by patients and healthcare providers alike. In-depth research into bladder cancer informs the development of targeted therapies and provides valuable insights into urothelial carcinoma, fostering cross-disciplinary approaches that promise enhanced treatment outcomes. For example, in January 2022, data from the American Cancer Society Inc. revealed that the estimated cases of urinary bladder cancer in the United States reached 83,730 in 2021, marking a 2.8% increase from the 81,400 cases reported in 2020. This upward trend in bladder cancer cases is poised to drive the urothelial carcinoma treatment market.

The growing demand for chemotherapy is anticipated to be a significant driver for the growth of the urothelial carcinoma treatment market in the foreseeable future. Chemotherapy is a medical treatment that employs drugs to target and eradicate rapidly dividing cells within the body, commonly employed in cancer treatment. Chemotherapy's pivotal role stems from its effectiveness in managing various stages of the disease, making it an integral approach in urothelial carcinoma treatment. For instance, as of June 2023, Mesothelioma.com, a medical information provider based in the United States, reports that approximately 25% of cancer patients in the US receive chemotherapy each year. Hence, the increasing demand for chemotherapy is set to propel the urothelial carcinoma treatment market.

The substantial investment costs associated with urothelial carcinoma therapeutics are acting as a deterrent to the growth of the urothelial carcinoma treatment market. The elevated costs of pharmaceuticals and treatment regimens may discourage individuals from seeking treatment and could lead to dissatisfaction with the treatment outcomes. For instance, the high price tags of immune checkpoint inhibitors such as nivolumab/ipilimumab and atezolizumab pose limitations to their cost-effectiveness. These drugs are utilized in urothelial carcinoma treatment, and their high costs can render effective treatment options financially out of reach for many. Consequently, the high investment costs for urothelial carcinoma therapeutics are hindering the market.

The prominent companies operating in the urothelial carcinoma treatment market are actively dedicated to introducing innovative products to enhance their competitive positions and meet the changing needs of their customers. For example, in March 2023, Nonacus Limited, a UK-based medical product manufacturer, unveiled GALEAS Bladder, a cutting-edge diagnostic test designed for the non-invasive detection of bladder cancer. GALEAS Bladder represents a significant advancement in bladder cancer diagnostics, offering a comprehensive molecular triage solution that seamlessly moves from sample collection to the final diagnostic report. It leverages a molecular biomarker with exceptional sensitivity to quickly and accurately identify bladder cancer, simplifying the diagnostic process and reducing the necessity for invasive procedures like cystoscopies. Developed in partnership with the University of Birmingham in the UK, GALEAS Bladder has undergone rigorous validation, involving over 600 patient samples from three distinct clinical cohorts in the UK. This extensive assessment underscores the remarkable performance of GALEAS Bladder, delivering high diagnostic accuracy (with a sensitivity exceeding 90% and specificity over 85%) and effectively catering to varying bladder cancer grades and stages.

In March 2021, ImmunityBio Inc., a US-based immunotherapy company specializing in bladder cancer treatment, underwent a merger with NantKwest Inc. for an undisclosed sum. This strategic merger positions ImmunityBio and NantKwest to offer significant novel treatment alternatives to patients by leveraging their respective leading platforms, expertise, and resources. The goal of this collaboration is to accelerate the advancement of their product pipeline. NantKwest Inc. is a clinical-stage immunotherapy company dedicated to the development of various immunotherapeutic solutions designed to address several cancers, including urothelial carcinoma.

Major players in the urothelial carcinoma treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., GlaxoSmithKline PLC, Astellas Pharma Inc., Agilent Technologies Inc., Eisai Co. Ltd., Incyte Corporation, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Seagen Inc., Lupin Limited, Genentech Inc., UroGen Pharma Inc., Acerta Pharma B.V., Asieris Pharmaceuticals Co. Ltd., Pacific Edge Limited, Protara Therapeutics Inc., Hamlet Pharma AB, CG Oncology Inc., AroCell AB, ImmunityBio Inc., IDL Biotech AB.

North America was the largest region in the urothelial carcinoma treatment market in 2023. The regions covered in urothelial carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urothelial carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urothelial carcinoma treatment market consists of revenues earned by entities by providing transurethral resection (TURBT) surgery and external beam radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The urothelial carcinoma treatment market also includes sales of platinum-based chemotherapy drugs such as cisplatin or carboplatin and immune checkpoint inhibitor drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Urothelial Carcinoma Treatment Market Characteristics

3. Urothelial Carcinoma Treatment Market Trends And Strategies

4. Urothelial Carcinoma Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Urothelial Carcinoma Treatment Market Size and Growth

  • 5.1. Global Urothelial Carcinoma Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Urothelial Carcinoma Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Urothelial Carcinoma Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Urothelial Carcinoma Treatment Market Segmentation

  • 6.1. Global Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Non-Invasive Urothelial Carcinoma Treatment
  • Invasive Urothelial Carcinoma Treatment
  • 6.2. Global Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Immunotherapy
  • Radiotherapy
  • Chemotherapy
  • 6.3. Global Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bladder Cancer
  • Urethral Cancer
  • Ureteric And Renal Pelvic Cancer
  • 6.4. Global Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Centers
  • Other End-Users

7. Urothelial Carcinoma Treatment Market Regional And Country Analysis

  • 7.1. Global Urothelial Carcinoma Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Urothelial Carcinoma Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Urothelial Carcinoma Treatment Market

  • 8.1. Asia-Pacific Urothelial Carcinoma Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Urothelial Carcinoma Treatment Market

  • 9.1. China Urothelial Carcinoma Treatment Market Overview
  • 9.2. China Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Urothelial Carcinoma Treatment Market

  • 10.1. India Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Urothelial Carcinoma Treatment Market

  • 11.1. Japan Urothelial Carcinoma Treatment Market Overview
  • 11.2. Japan Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Urothelial Carcinoma Treatment Market

  • 12.1. Australia Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Urothelial Carcinoma Treatment Market

  • 13.1. Indonesia Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Urothelial Carcinoma Treatment Market

  • 14.1. South Korea Urothelial Carcinoma Treatment Market Overview
  • 14.2. South Korea Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Urothelial Carcinoma Treatment Market

  • 15.1. Western Europe Urothelial Carcinoma Treatment Market Overview
  • 15.2. Western Europe Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Urothelial Carcinoma Treatment Market

  • 16.1. UK Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Urothelial Carcinoma Treatment Market

  • 17.1. Germany Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Urothelial Carcinoma Treatment Market

  • 18.1. France Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Urothelial Carcinoma Treatment Market

  • 19.1. Italy Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Urothelial Carcinoma Treatment Market

  • 20.1. Spain Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Urothelial Carcinoma Treatment Market

  • 21.1. Eastern Europe Urothelial Carcinoma Treatment Market Overview
  • 21.2. Eastern Europe Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Urothelial Carcinoma Treatment Market

  • 22.1. Russia Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Urothelial Carcinoma Treatment Market

  • 23.1. North America Urothelial Carcinoma Treatment Market Overview
  • 23.2. North America Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Urothelial Carcinoma Treatment Market

  • 24.1. USA Urothelial Carcinoma Treatment Market Overview
  • 24.2. USA Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Urothelial Carcinoma Treatment Market

  • 25.1. Canada Urothelial Carcinoma Treatment Market Overview
  • 25.2. Canada Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Urothelial Carcinoma Treatment Market

  • 26.1. South America Urothelial Carcinoma Treatment Market Overview
  • 26.2. South America Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Urothelial Carcinoma Treatment Market

  • 27.1. Brazil Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Urothelial Carcinoma Treatment Market

  • 28.1. Middle East Urothelial Carcinoma Treatment Market Overview
  • 28.2. Middle East Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Urothelial Carcinoma Treatment Market

  • 29.1. Africa Urothelial Carcinoma Treatment Market Overview
  • 29.2. Africa Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Urothelial Carcinoma Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Urothelial Carcinoma Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Urothelial Carcinoma Treatment Market Competitive Landscape
  • 30.2. Urothelial Carcinoma Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Urothelial Carcinoma Treatment Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Sanofi S.A.
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. AstraZeneca PLC
  • 31.5. Abbott Laboratories Inc.
  • 31.6. GlaxoSmithKline PLC
  • 31.7. Astellas Pharma Inc.
  • 31.8. Agilent Technologies Inc.
  • 31.9. Eisai Co. Ltd
  • 31.10. Incyte Corporation
  • 31.11. Hikma Pharmaceuticals PLC
  • 31.12. Amneal Pharmaceuticals LLC
  • 31.13. Seagen Inc.
  • 31.14. Lupin Limited
  • 31.15. Genentech Inc.

32. Global Urothelial Carcinoma Treatment Market Competitive Benchmarking

33. Global Urothelial Carcinoma Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Urothelial Carcinoma Treatment Market

35. Urothelial Carcinoma Treatment Market Future Outlook and Potential Analysis

  • 35.1 Urothelial Carcinoma Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Urothelial Carcinoma Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Urothelial Carcinoma Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer